Publications

  1. Budhiraja P, Schold JD, Heilman RL, Malamon J, Kaplan B. Integrating Epidemiological Data and Conditional Probabilistic Approaches in Clinical Decision-making: A Focus on Kidney Transplantation. Transplantation. 2024 Nov 1; 108 (11):2159-2161 Epub 2024 July 24
    View PubMed
  2. Budhiraja P, Nguyen M, Heilman R, Kaplan B. The Role of Allograft Nephrectomy in the Failing Kidney Transplant. Transplantation. 2023 Dec 1; 107 (12):2486-2496 Epub 2023 May 01
    View PubMed
  3. Nair S, Ravichandran R, Heilman R, Jaramillo A, Buras M, Kaplan B, Itabashi Y, Ramon D, Hacke K, Smith B, Mohanakumar T. Study of association between antibodies to non-HLA kidney self-antigens and progression to chronic immune injury after kidney transplantation. Hum Immunol. 2023 Oct; 84 (10):509-514 Epub 2023 July 26
    View PubMed
  4. Sawinski D, Lai JC, Pinney S, Gray AL, Jackson AM, Stewart D, Levine DJ, Locke JE, Pomposelli JJ, Hartwig MG, Hall SA, Dadhania DM, Cogswell R, Perez RV, Schold JD, Turgeon NA, Kobashigawa J, Kukreja J, Magee JC, Friedewald J, Gill JS, Loor G, Heimbach JK, Verna EC, Walsh MN, Terrault N, Testa G, Diamond JM, Reese PP, Brown K, Orloff S, Farr MA, Olthoff KM, Siegler M, Ascher N, Feng S, Kaplan B, Pomfret E. Addressing sex-based disparities in solid organ transplantation in the United States - a conference report. Am J Transplant. 2023 Mar; 23 (3):316-325 Epub 2023 Jan 12
    View PubMed
  5. Budhiraja P, Heilman RL, Edwards AS, Kaplan B. The Problem With Predicting Uncommon Events: The Critical Effect of Prevalence in Test Performance. Transplant Proc. 2022 Sep; 54 (7):1742-1744 Epub 2022 July 30
    View PubMed
  6. Chakkera HA, Kaplan B, Budhiraja P, Behmen S, Fitz-Patrick D, Butterfield RJ. VO2peak prior to transplant differentiates survival post kidney transplant. Clin Transplant. 2022 Feb; 36 (2):e14517 Epub 2021 Nov 07
    View PubMed
  7. Budhiraja P, Kaplan B, Kalot M, Alayli AE, Dimassi A, Chakkera HA, Heilman R, Edwards AS, Mustafa RA. Current State of Evidence on Kidney Transplantation: How Fragile Are the Results? Transplantation. 2022 Feb 1; 106 (2):248-256
    View PubMed
  8. Budhiraja P, Kalot MA, Alayli AE, Dimassi A, Kaplan B, Chakkera HA, Mustafa RA. Reporting and Handling of Missing Participant Data in Systematic Reviews of Kidney Transplant Studies. Transplantation. 2021 Aug 1; 105 (8):1708-1717
    View PubMed
  9. Kilambi V, Bui K, Hazen GB, Friedewald JJ, Ladner DP, Kaplan B, Mehrotra S. Evaluation of Accepting Kidneys of Varying Quality for Transplantation or Expedited Placement With Decision Trees. Transplantation. 2019 May; 103 (5):980-989
    View PubMed
  10. Heilman RL, Kaplan B. Is Recipient HLA-B51 Status Protective for the Risk of BK Infection After Kidney Transplantation? Transplantation 2019 Mar; 103 (3):461-462
    View PubMed
  11. Heilman RL, Srinivas TR, Kaplan B. On Reporting of the Outcomes from Clinical Trials; a Call to Order. Transplantation 2018 Dec; 102 (12):1966-1967
    View PubMed
  12. Reddy KS, Kaplan B. Donor Hypothermia and Organ Transplantation. Transplantation 2018 Nov; 102 (11):1789-1790
    View PubMed
  13. Chakkera HA, Angadi SS, Heilman RL, Kaplan B, Scott RL, Bollempalli H, Cha SS, Khamash HA, Huskey JL, Mour GK, Sukumaran Nair S, Singer AL, Reddy KS, Mathur AK, Moss AA, Hewitt WR Jr, Qaqish I, Behmen S, Keddis MT, Unzek S, Steidley DE. Cardiorespiratory Fitness (Peak Oxygen Uptake): Safe and Effective Measure for Cardiovascular Screening Before Kidney Transplant. J Am Heart Assoc. 2018 May 31; 7 (11)
    View PubMed
  14. Abdelwahab Elhamahmi D, Heilman RL, Smith B, Huskey J, Khamash H, Kaplan B. Early Conversion to Belatacept in Kidney Transplant Recipients With Low Glomerular Filtration Rate. Transplantation. 2018 Mar; 102 (3):478-483
    View PubMed
  15. Ilyas M, Colegio OR, Kaplan B, Sharma A. Cutaneous Toxicities From Transplantation-Related Medications. Am J Transplant. 2017 Nov; 17 (11):2782-2789 Epub 2017 May 30
    View PubMed
  16. Kransdorf EP, Pando MJ, Gragert L, Kaplan B. HLA Population Genetics in Solid Organ Transplantation. Transplantation. 2017 Sep; 101 (9):1971-1976
    View PubMed
  17. Chakkera HA, Sharif A, Kaplan B. Negative Cardiovascular Consequences of Small Molecule Immunosuppressants. Clin Pharmacol Ther. 2017 Aug; 102: (2)269-276.
    View PubMed
  18. Heilman RL, Green EP, Reddy KS, Moss A, Kaplan B. Potential Impact of Risk and Loss Aversion on the Process of Accepting Kidneys for Transplantation. Transplantation. 2017 Jul; 101 (7):1514-1517
    View PubMed
  19. Qazi Y, Shaffer D, Kaplan B, Kim DY, Luan FL, Peddi VR, Shihab F, Tomlanovich S, Yilmaz S, McCague K, Patel D, Mulgaonkar S. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. Am J Transplant. 2017 May; 17 (5):1358-1369 Epub 2017 Jan 04
    View PubMed
  20. Goss M, Reese J, Kueht M, Vierling JM, Mindikoglu AL, Sussman NL, Kaplan B, Wood RP, Rana AA. A Surge in cadaveric liver donors and a national narcotic epidemic: Is there an association? Liver Transpl 2017 May; 23 (5):698-700
    View PubMed
  21. Kurian SM, Whisenant T, Mas V, Heilman R, Abecassis M, Salomon DR, Moss A, Kaplan B. Biomarker Guidelines for High-Dimensional Genomic Studies in Transplantation: Adding Method to the Madness. Transplantation. 2017 Mar; 101 (3):457-463
    View PubMed
  22. Chakkera HA, Kudva Y, Kaplan B. Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus. Clin Pharmacol Ther. 2017 Jan; 101 (1):114-120 Epub 2016 Nov 21
    View PubMed
  23. Abecassis M, Kaplan B. Caveat emptor: the devil is still in the detail. Nat Rev Nephrol. 2017 Jan; 13 (1):60 Epub 2016 Nov 14
    View PubMed
  24. King RW, Baca MJ, Armenti VT, Kaplan B. Pregnancy Outcomes Related to Mycophenolate Exposure in Female Kidney Transplant Recipients. Am J Transplant. 2017 Jan; 17 (1):151-160 Epub 2016 July 15
    View PubMed
  25. Keddis MT, El-Zoghby Z, Kaplan B, Meeusen JW, Donato LJ, Cosio FG, Steidley DE. Soluble ST2 does not change cardiovascular risk prediction compared to cardiac troponin T in kidney transplant candidates. PLoS One. 2017; 12 (7):e0181123 Epub 2017 July 13
    View PubMed
  26. Heilman RL, Smith ML, Smith BH, Qaqish I, Khamash H, Singer AL, Kaplan B, Reddy KS. Progression of Interstitial Fibrosis during the First Year after Deceased Donor Kidney Transplantation among Patients with and without Delayed Graft Function. Clin J Am Soc Nephrol. 2016 Dec 7; 11 (12):2225-2232 Epub 2016 Oct 24
    View PubMed
  27. Moss A, Kaplan B. Transplantation: Utilizing the transcriptome to predict allograft fibrosis. Nat Rev Nephrol. 2016 Nov; 12 (11):652-653 Epub 2016 Sept 19
    View PubMed
  28. Heilman RL, Mathur A, Smith ML, Kaplan B, Reddy KS. Increasing the Use of Kidneys From Unconventional and High-Risk Deceased Donors. Am J Transplant. 2016 Nov; 16 (11):3086-3092 Epub 2016 June 14
    View PubMed
  29. Chakkera HA, Schold JD, Kaplan B. P Value: Significance Is Not All Black and White. Transplantation 2016 Aug; 100 (8):1607-9
    View PubMed
  30. Neapolitan R, Jiang X, Ladner DP, Kaplan B. A Primer on Bayesian Decision Analysis With an Application to a Kidney Transplant Decision. Transplantation. 2016 Mar; 100 (3):489-96
    View PubMed
  31. McCullough JM, Kaplan B. A Random Walk Through Large Data: Caveats Regarding the Potential for False Inference. Transplantation. 2016 Jan; 100: (1)18-22.
    View PubMed
  32. Coletta DK, Campbell LE, Weil J, Kaplan B, Clarkson M, Finlayson J, Mandarino LJ, Chakkera HA. Changes in Pre- and Post-Exercise Gene Expression among Patients with Chronic Kidney Disease and Kidney Transplant Recipients. PLoS One. 2016; 11 (8):e0160327 Epub 2016 Aug 12
    View PubMed
  33. Singh SK, Kaplan B, Kim SJ. Multivariable Regression Models in Clinical Transplant Research: Principles and Pitfalls. Transplantation. 2015 Dec; 99: (12)2451-7.
    View PubMed
  34. Rodrigue JR, Schold JD, Morrissey P, Whiting J, Vella J, Kayler LK, Katz D, Jones J, Kaplan B, Fleishman A, Pavlakis M, Mandelbrot DA, KDOC Study Group. Predonation Direct and Indirect Costs Incurred by Adults Who Donated a Kidney: Findings From the KDOC Study. Am J Transplant. 2015 Sep; 15(9):2387-93. Epub 2015 May 05.
    View PubMed
  35. Skaro AI, Hazen G, Ladner D, Kaplan B. Organ Transplantation: An Introduction to Game Theory. Transplantation. 2015 Jul; 99(7):1316-20.
  36. Viswesh V, Yost SE, Kaplan B. The prevalence and implications of BK virus replication in non-renal solid organ transplant recipients: A systematic review. Transplant Rev (Orlando). 2015 Jul; 29(3):175-180.
  37. Gupta A, Ho B, Ladner DP, Kang J, Skaro A, Kaplan B. Program-specific Reports: A Guide to the Debate. Transplantation. 2015 Jun; 99(6):1109-12.
  38. Loucks J, Yost S, Kaplan B. An introduction to basic pharmacokinetics. Transplantation. 2015 May; 99(5):903-7.
  39. Abecassis M, Kaplan B. Transplantation: Biomarkers in transplantation—the devil is in the detail. Nat Rev Nephrol. 2015 Apr; 11(4):204-5.
  40. Rana A, Kaplan B, Riaz IB, Porubsky M, Habib S, Rilo H, Gruessner AC, Gruessner RW. Geographic inequities in liver allograft supply and demand: does it affect patient outcomes? Transplantation. 2015 Mar; 99(3):515-20.
  41. Reeve J, Halloran PF, Kaplan B. Common errors in the implementation and interpretation of microarray studies. Transplantation. 2015 Mar; 99(3):470-5.
  42. Rana A, Gruessner A, Agopian VG, Khalpey Z, Riaz IB, Kaplan B, Halazun KJ, Busuttil RW, Gruessner RW. Survival benefit of solid-organ transplant in the United States. JAMA Surg 1. 2015 Mar 1; 150(3):252-9.
  43. Rana A, Gruessner A, Agopian VG, Khalpey Z, Riaz IB, Kaplan B, Halazun KJ, Busuttil RW, Gruessner RW. Survival benefit of solid-organ transplant in the United States. JAMA Surg. 2015 Mar 1; 150 (3):252-9
    View PubMed
  44. Rana A, Kaplan B, Riaz IB, Porubsky M, Habib S, Rilo H, Gruessner AC, Gruessner RW. Geographic inequities in liver allograft supply and demand: does it affect patient outcomes? Transplantation. 2015 Mar; 99 (3):515-20
    View PubMed
  45. Mehrotra S, Kilambi V, Gilroy R, Ladner DP, Klintmalm GB, Kaplan B. Modeling the allocation system: principles for robust design before restructuring. Transplantation. 2015 Feb; 99(2):278-81.
  46. Hogan JL, Rosenthal SJ, Yarlagadda SG, Jones JA, Schmitt TM, Kumer SC, Kaplan B, Deas SL, Nawabi AM. Late-onset renal vein thrombosis: A case report and review of the literature. Int J Surg Case Rep. 2015; 6C:73-6.
  47. Srinivas TR, Ho B, Kang J, Kaplan B. Post hoc analyses: after the facts. Transplantation. 2015 Jan; 99(1):17-20.
  48. Bray RA, Brannon P, Breitenbach C, Bryan C, Chen DF, Lai J, McRackeen T, Kirk A, Kaplan B, Pearson T, Gebel HM. The new OPTN kidney allocation policy: potential for inequitable access among highly sensitized patients. Am J Transplant. 2015 Jan; 151(284-5).
  49. Gupta A, Kumer S, Kaplan B. Novel immunosuppressive strategies for composite tissue allografts. Curr Opin Organ Transplant. 2014 Dec; 19(6):552-7.
  50. Gupta A, Chen G, Kaplan B. KDPI and donor selection . Am J Tranplant. 2014 Nov; 14.
  51. Bakhtar O, Thajudeen B, Braunhut BL, Yost SE, Bracamonte ER, Sussman AN, Kaplan B. A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab. Transplantation 15. 2014 Aug 15; 98(3):e17-8.
  52. Gupta A, Kaplan B. Transplantation: CNIs to mTOR inhibitors--effects on allosensitization? Nat Rev Nephrol. 2014 Aug; 10(8):425-6.
  53. Kaplan B, Ilahe A. Quantifying risk of kidney donation: the truth is not out there (yet). Am J Transplant. 2014 Aug; 14(8):1715-6.
  54. Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando). 2014 Jul; 28(3):126-33.
  55. Chong AS, Kaplan B. New kid on the pretransplant block: IgG recognizing apoptotic cells. Am J Transplant. 2014 Jul; 14.
  56. Shihab F, Christians U, Smith L, Wellen JR, Kaplan B. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol Jun. 2014 Jun; 31(1):22-32.
  57. van Gelder T, Bouamar R, Shuker N, Hesselink D, Weimar W, Kaplan B, Bernasconi C. The optimal MMF dose in tacrolimus treated patients. Am J Transplant. 2014 May; 14.
  58. Lo DJ, Kaplan B, Kirk AD. Biomarkers for kidney transplant rejection. Nat RevNephrol. 2014 Apr; 10(4):215-25.
  59. Rana A, Petrowsky H, Kaplan B, Jie T, Porubsky M, Habib S, Rilo H, Gruessner AC, Gruessner RW. Early liver retransplantation in adults. Transpl Int Feb. 2014 Feb; 27(2):141-51.
  60. Yost SE, Echeverria A, Jie T, Kaplan B. Panresistant cytomegalovirus in a kidney transplant recipient. Pharmacotherapy. 2014 Jan; 34(1):e1-3.
  61. Kaplan B. Report cards and quality: do center report cards predict quality or simply predict the next report card?. Am J Transplant. 2014 Jan; 14(1):238.
  62. Leeaphorn N, Sampaio MS, Natal N, Mehrnia A, Kamgar M, Huang E, Kalantar-Zadeh K, Kaplan B, Bunnapradist S. Renal Transplant Outcomes in Waitlist Candidates with a Previous Inactive Status Due to Being Temporarily Too Sick. Clin Transpl. 2014; 117-24
    View PubMed
  63. Gillespie M, Yost SE, Meister E, Kaplan B. A cautionary tale of BK virus. Transpl Int. 2013 Nov; 26(11):e99.
  64. Srinivas TR, Kaplan B. Urinary biomarkers and kidney transplant rejection: fine-tuning the radar. Am J Transplantation. 2013 Oct; 13(10):2519-21.
  65. Harton GL, Munne S, Surrey M, Grifo J, Kaplan B, McCulloh DH, Griffin DK, Wells D. Diminished effect of maternal age on implantation after preimplantation genetic diagnosis with array comparative genomic hybridization. Fertil Steril. 2013 Sep.
  66. Gaber AO, Alloway RR, Bodziak K, Kaplan B, Bunnapradist S. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation 27. 2013 Jul 27; 96(2):191-7.
  67. Rana A, Kaplan B, Jie T, Porubsky M, Habib S, Rilo H, Gruessner AC, Gruessner RW. A critical analysis of early death after adult liver transplants. ClinTransplant. 2013 Jul-Aug; 27(4):E448-53.
  68. Koppula S, Yost SE, Sussman A, Bracamonte ER, Kaplan B. Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients. Clin Transplant. 2013 Jul-Aug; 27(4):591-7.
  69. 24: Rana A, Jie T, Porubsky M, Habib S, Rilo H, Kaplan B, Gruessner A, Gruessner R. The survival outcomes following liver transplantation (SOFT) score: validation with contemporaneous data and stratification of high-risk cohorts. ClinTransplant. 2013 Jul-Aug; 27(4):627-32.
  70. Turgeon N, Kaplan B. Risky business: models of risk in transplant. Am J Transplant. 2013 May; 13(5):1121-2.
  71. Bouamar R, Shuker NM, Hesselink DA, Weimar W, Ekberg H, Bernasconi C, Kaplan B, Van Gelder T. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation; a pooled analysis from three randomized-controlled clinical trials. Am J Transplant. 2013 May; 13(5):1253-61.
  72. Danielson KK, Hatipoglu B, Kinzer K, Kaplan B, Martellotto J, Qi M, Mele A, Benedetti E, Oberholzer J. Reduction in carotid intima-media thickness after pancreatic islet transplantation in patients with type 1 diabetes. Diabetes Care. 2013 Feb; 36(2):450-6.
  73. Yost SE, Kaplan B. Comparing kidney transplant outcomes; caveats and lessons. Nephrol Dial Transplant. 2013 Jan; 28(1):9-11.
  74. Van Gelder T, Kaplan B, Ekberg H. Tacrolimus exposure does not impact T-cell mediated rejection. Transplantation. 2013.
  75. Boyer T, Kaplan B. Renal failure and liver transplantation. Clinical Liver Disease. 2013.
  76. Sun Q, Hall EC, Huang Y, Chen P, Dibadj K, Murawski M, Shraybam R, Van Kirk K, Tang V, Peng R, Patton PR, Clare-Salzler MJ, Kaplan B, Segev DL, Womer KL. Pre-transplant myeloid dendritic cell deficiency associated with cytomegalovirus infection and death after kidney transplantation. Transpl Infect Dis. 2012 Dec; 14(6):618-25.
  77. Kaplan B, Sweeney JF. Assessing 30-day hospital readmission after renal transplantation: a complex task. Am J Transplant. 2012 Dec; 12(12):3171-2.
  78. Tzvetanov I, Spaggiari M, Oberholzer J, Setty S, Stephenson A, Thielke J, West-Thielke P, Jeon H, Danielson KK, Kaplan B, Benedetti E. Cell population in spleens during antibody-mediated rejection: pathologic and clinical findings. Transplantation. 2012 Aug 15; 94(3):255-62.
  79. Chisholm-Burns MA, Erickson SR, Spivey CA, Kaplan B. Health-related quality of life and employment among renal transplant recipients. Clin Transplant May-Jun. 2012 May-Jun; 26(3):411-7.
  80. Blume OR, Yost SE, Kaplan B. Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes. J Transplant. 2012; 2012:201754.
  81. Stevens RB, Lane JT, Boerner BP, Miles CD, Rigley TH, Sandoz JP, Nielsen KJ, Skorupa JY, Skorupa AJ, Kaplan B, Wrenshall LE. Single-dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemia. Clin Transplant. 2012 Jan-Feb; 26(1):123-32.
  82. Srinivas TR, Kaplan B. Transplantation in 2011: New agents, new ideas and new hope. Nat Rev Nephrol. 2011 Dec 20; 8(2):74-5.
  83. Yost SE, Byrne R, Kaplan B. Transplantation: mTOR inhibition in kidney transplant recipients. Nat Rev Nephrol. 2011 Aug 30; 7(10):553-5.
  84. Yost SE, Srinivas T, Kaplan B. Ethical considerations regarding disparities pertaining to kidney transplant patients. Clin Pharmacol. 2011 Aug; 90(2):212-4.
  85. Ekberg H, van Gelder T, Kaplan B, Bernasconi C. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. Transplantation. 2011 Jul 15; 92(1):82-7.
  86. Meier-Kriesche HU, Kaplan B. The search for CNI free immunosuppression: no free lunch. Am J Transplant. 2011 Jul; 11(7):1355-6.
  87. Askar M, Schold JD, Eghtesad B, Flechner SM, Kaplan B, Klingman L, Zein NN, Fung J, Srinivas TR. Combined liver-kidney transplants: allosensitization and recipient outcomes. Transplantation. 2011 Jun 15; 91(11):1286-92.
  88. Stevens RB, Lane JT, Oerner BP, Miles CD, Rigley TH, Sandoz JP, Nielsen KJ, Skorupa JY, Skorupa AJ, Kaplan B, Wrenshall LE. Single-dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemia. Clin Transplantation. 2011 Mar.
  89. Sellares J, de Freitas DG, Mengel M, Sis B, Hidalgo LG, Matas AJ, Kaplan B, Halloran PF. Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases. Am J Transplant. 2011 Mar; 11(3):489-9.
  90. Segev D, Massie A, Schold J, Kaplan B. If you are bnot fit, you must not quit: observational studies and weighing the evidence. Am J Transplant. 2011 Feb; 11:1-2.
  91. Chisholm-Burns MA, Erickson SR, Spivey CA, Gruessner RW, Kaplan B. Concurrent validity of kidney transplant questionnaire in US renal transplant recipients. Patient Prefer Adherence. 2011; 5:517-22.
  92. Srinivas TR, Kaplan B, Meier-Kriesche HU. The noninferiority trial: don't do it. Am J Transplant. 2010 Dec; 12(571-3). Epub 0
  93. Schold J, Sehgal A, Srinivas T, Poggio E, Navaneethan S, Kaplan B. Marked variation of the association of ESRD duration before and after wait listing on kidney transplant outcomes. Am J Transplant. 2010 Sep; 10(9):2008-16.
  94. Avery R, Kaplan B. Immunosuppressive agents and CMV risk in the VICTOR study. Am J Transplant. 2010 Aug; 10(8):1727-8.
  95. Einecke G, Reeve J, Sis B, Mengel M, Hidalgo L, Famulski KS, Matas A, Kasiske B, Kaplan B, Halloran PF. A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest. 2010 Jun; 120(6):1862-72.
  96. Schold JD, Kaplan B. The elephant in the room: failings of current clinical endpoints in kidney transplantation. Am J Transplant. 2010 May; 10(5):1163-6.
  97. Kaplan B, Gaston RS, Meier-Kriesche HU, Bloom RD, Shaw LM. Mycophenolic acid exposure in high- and low-weight renal transplant patients after dosing with mycophenolate mofetil in the Opticept trial. Ther Drug Monit. 2010 Apr; 32(2):224-7.
  98. Famulski K, Einecke G, Sis B, Mengel M, Hidalgo L, Kaplan B, Halloran P. Defining the canonical form of T-cell-mediated rejection in human kidney transplants. Am J Transplant. 2010 Apr; 10(9):810-20.
  99. Kaplan B, Jie T, Diana R, Renz J, Whinery A, Stubbs N, Bracamonte E, Spier C, Schubart P, Rilo H, Gruessner R. Histopathology and immunophenotype of the spleen during acute antibody-mediated rejection. Am J Transplant. 2010 Apr; 10(5):1316-20.
  100. Sis B, Einecke G, Chang J, Hidalgo LG, Mengel M, Kaplan B, Halloran P. Cluster analysis of lesions in nonselected kidney transplant biopsies: microcirculation changes, tubulointerstitial inflammation and scarring. Am J Transplant. 2010 Feb; 10(7):421-30.
  101. Womer KL, Huang Y, Herren H, Dibadj K, Peng R, Murawski M, Shraybman R, Patton P, Clare-Salzler MJ, Kaplan B. Dendritic cell deficiency associated with development of BK viremia and nephropathy in renal transplant recipients. Transplantation. 2010 Jan 15; 89(1):115-23.
  102. Shapiro R, Kaplan B. Native renal cysts and dialysis duration are risk factors for renal cell in renal transplant recipients. Am J Transplant. 2010; 11(1).
  103. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant. 2009 Oct; 9(10):2312-23.
  104. Schold JD, Kaplan B. AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. Am J Transplant. 2009 Sep; 9(9):2067-74.
  105. Reeve J, Einecke G, mengel M, Sis B, Kayser N, Kaplan B, Halloran PF. Diagnosing rejection in renal transplants: a comparison of molecular-and histopathology-based approaches . Am J Transplant. 2009 Aug; 9(8):1802-10.
  106. Nanovic L, Kaplan B. Reliability of Medicare claim forms for outcome studies in kidney transplant recipients: epidemiology in clinical outcome trials. Clin J Am Soc Nephrol. 2009 Jul; 4(7):1156-8.
  107. Aston RS, Murphy M, Kaplan B, Shah T, Mulgaonkar S, Meier H, Bloom R, Cibrik D, Shaw L, Angelis M. Fixed-or controlled-dose mycophenolate mofetil with standard-or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009 Jul; 9(7):1607-19.
  108. Bunnag S, Einecke G, Reeve J, Jhangri GS, Mueller TF, Sis B, Hidalgo LG, Mengel M, Kayser D, Kaplan B, Halloran PF. Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol. 2009 May; 20(5):1149-60.
  109. Gangemi A, Tzvetanov IG, Beatty E, Oberholzer J, Testa G, Sankary HN, Kaplan B, Benedetti E. Lessons learned in pediatric small bowel and liver transplantation from living-related donors. Transplantation. 2009 Apr 15; 87(7):1027-30.
  110. Kaplan B, Schold J. Transplantation: neural networks for predicting graft survival. Nat Rev Nephrol. 2009 Apr; 5(4):190-2.
  111. Beier UH, Kaplan B, Setty S, Samuel S, Mathew AV, Oberholzer J, Benedetti E, John E. Electrolyte imbalances in pediatric living related small bowel transplantation. Transplantation. 2009 Apr; 87(7):1027-30.
  112. Thielke JJ, West-Thielke PM, Herren HL, Bareato U, Ommert T, Vidanovic V, Campbell-Lee SA, Tzvetanov IG, Sankary HN, Kaplan B, Benedetti E, Oberholzer J. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation. 2009 Jan 27; 87(2):268-73.
  113. CITR Research Group. 2007 update on allogeneic islet transplantation from the Collaborative Islet Transplant Registry (CITR). Cell Transplant. 2009; 18(7):753-67.
  114. Nanovic L, Kaplan B. The advantage of live-donor kidney transplantation in older recipients. Nat Clin Pract Nephrol. 2009 Jan; 5(1):18-9.
  115. Mengel M, Reeve J, Bunnag S, Einecke G, Sis B, Mueller T, Kaplan B, Hallorn PF. Molecularcorrelates of scarring in kidney transplants: the emergency of mast cell transcripts. Am J Transplant. 2009 Jan; 9(1):169-78.
  116. Alejandro R Barton FB Hering BJ Wease S, Collaborative Islet Transplant Registry Investigators. 2008 Update from the Collaborative Islet Transplant Registry. Transplantation. 2008 Dec 27; 86(12):1783-8.
  117. Kaplan B, West-Thielke P, Herren H, Gill J, Knoll GA, Oberholzer J, Sankary H, Benedetti E. Reported isolated pancreas rejection is associated with poor kidney outcomes in recipients of a simultaneous pancreas kidney transplant. Transplantation. 2008 Nov 15; 86(9):1229-33.
  118. Howard RJ, Kaplan B. The time is now: formation of true transplant centers. Am J Transplant. 2008 Nov; 8(11):2225-9.
  119. Womer KL, Patton PR, Kaplan B. Aggressive post-transplant monitoring of more importance to successful outcome following re-transplantation for BK virus nephropathy than absence of pretransplant viremia. Transpl Int. 2008 Nov; 21(11):1103-4.
  120. Kaplan B, Schold JD. The practical utility of an economic analysis of calcineurin withdrawal following renal transplantation. J Am Soc Nephrol. 2008 Sep; 19(9):1627-8.
  121. Schold JD, Kaplan B. Design and analysis of clinical trials in transplantation: principles and pitfalls. Am J Transplant. 2008 Sep; 8(9):1779-85.
  122. Campara M, West-Thielke P, Thielke J, Ommert T, Oberholzer J, Benedetti E, Kaplan B. ABO incompatible renal transplantation in an HIV-seropositive patient. Transplantation. 2008 Jul 15; 86(1):176-8.
  123. Halloran P, Bromberg J, Kaplan B, Vincenti F. Tolerance versus immunosuppression: a perspective. Am J Transplant. 2008 Jul; 8(7):1365-6.
  124. Gangemi A, Salehi P, Hatipoglu B, Martellot J, Barbara B, Kuechle JB, qi M, Wang Y, Pallan P, Owens C, Bui J, West D, Kaplan B, Benedetti E, Oberholzer J. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant. 2008 Jun; 8(6):1250-61.
  125. Rodrigue JR, Guenther R, Kaplan B, Mandelbrot DA, Pavlakis M, Howard RJ. Measuring the expectations of kidney donors: initial psychometric properties of the Living Donation Expectancies Questionnaire. Transplantation. 2008 May 15; 85(9):1230-4.
  126. Miller G, Kaplan B. Prophylaxis versus preemptive protocols for CMV: do they impact graft survival?. Am J Transplant. 2008 May; 8(5):913-4.
  127. Rodrigue JR, Cornell DL, Kaplan B, Howard RJ. A randomized trial of a home-based educational approach to increase live donor kidney transplantation: effects in blacks and whites. Am J Kidney Dis. 2008 Apr; 51(4):663-70.
  128. West P, Schmiedeskamp M, Neeley H, Oberholzer J, Benedetti E, Kaplan B. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation. Transpl Infect Dis. 2008 Apr; 10(2):129-32.
  129. Rodrigue JR, Cornell DL, Kaplan B, Howard RJ. Patients' willingness to talk to others about living kidney donation. Prog Transplant. 2008 Mar; 18(1):25-31.
  130. Kaplan B, West P, neeley H, Martello J, Gangemi A, Sankary H, Benedetti E, Oberholzer JO. Use of low dose tacrolimus, mycophenolate mofetil and maintenance IL-2 receptor blockade in an islet transplant recipient . Clin Transpl. 2008 Mar-Apr; 22(2):250-3.
  131. Simon G, Parker M, Ramiya V, Wasserfall C, Huang Y, Bresson D, Schwartz RF, Campbell-Thompson M, Tenace L, Brusko T, Xue S, Scaria A, Lukason M, Eisenbeis S, Williams J, Clare-Salzler M, Schatz D, Kaplan B, Von Herrath M, Womer K, Atkinson MA. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes. 2008 Feb; 57(2):405-14.
  132. West-Thielke P, herren H, Thielke J, Obreholzer J, Sankary H, Raofi V, Benedetti E, Kaplan B. Results of positive cross-match transplantation in African American renal transplant recipients. Am J Transplant. 2008 Feb; 8(2):348-54.
  133. Meier-Kriesche HU, Magee J, Kaplan B. Trials and tribulations of steroid withdrawal after kidney transplantation. Am J Transplant. 2008 Feb; 8(2):265-6.
  134. Meier-Kriesche UH, Kaplan B, Setty S, Samuel S, Mathew AV, Oberholzer J, Benedetti E, John E. Electrolyte imbalances in pediatric living related small bowel transplantation. Transplantation. 2008 Jan 27; 85(2):217-23.
  135. Sis B, Kaplan B, Halloran PF. Histologic findings from positive crossmatch or ABO-incompatible renal allografts: accommodation or chronic allograft injury. Am J Transplant. 2007 Dec; 6(12):2712-22.
  136. Mueller T, Einecke G, Reeve J, Sis B, Mengel M, Wishart D, Kaplan B, Halloran P. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant. 2007 Dec; 7(12):2712-22.
  137. West-Thielke P, Kaplan B. Therapeutic monitoring of mycophenolic acid: is there clinical utility?. Am J Transplant. 2007 Nov; 7(11):2441-2.
  138. Bromberg J, Kaplan B, Halloran P, Robertson RP. The islet transplant experiment: time for a reassessment. Am J Transplant. 2007 Oct; 7(10):2217-8.
  139. Womer KL, Guerra G, Dibadj K, Huang Y, Kazory A, Kaplan B, Srinivas TR. Immunosuppression reduction for BK virus nephropathy: a case for caution. Transpl Infect Dis. 2007 Sep; 9(3):244-8.
  140. Rodrigue JR, Reed AI, Nelson DR, Jamieson I, Kaplan B, Howard RJ. The financial burden of transplantation: a single-center survey of liver and kidney transplant recipients. Transplantation. 2007 Aug 15; 84(3):295-300.
  141. Thielke J, Kaplan B, Benedetti E. The role of ABO-incompatible living donors in kidney transplantation: state of the art. Semin Nephrol Jul. 2007 Jul; 27(4):408-13.
  142. Tang IY, Meier-Kriesche HU, Kaplan B. Immunosuppressive strategies to improve outcomes of kidney transplantation. Semin Nephrol. 2007 Jul; 27(4):377-92.
  143. Kaplan B, Williams R. Organ donation: the gift, the weight and the tyranny of good acts. Am J Transplant. 2007 Mar; 7(3):497-8.
  144. Kaplan B, Budde K. Lessons from the CAESAR study: calcineurin inhibitors-can't live with them and can't live without them. Am J Transplant. 2007 mar; 7(3):495-6.
  145. Rodrigue JR, Cornell DL, Lin JK, Kaplan B, Howard RJ. Increasing live donor kidney transplantation: a randomize controlled trail of a home-based educational intervention. Am J Transplant. 2007 Feb; 7(2):394-401.
  146. Kaplan B, Gangemi A, Thielke J, Oberholzer J, Sankary H, Benedetti E. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation. 2007 Jan 15; 83(1):99-100.
  147. Jeong H, Kaplan B. Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol. 2007 Jan; 2(1):184-91.
  148. West-Thielke P, Kaplan B. Drug concentrations as a biomarker in transplant. Therapeutic Reviews. 2007.
  149. Kaplan B. Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome. Curr Med Res Opin. 2006 Dec; 22(12):2355-64.
  150. Feng S, Barr M, Roberts J, Oberbauer R, Kaplan B. Developments in clinical islet, liver thoracic, kidney and pancreas transplantation in the last 5 years. Am J Transplant. 2006 Aug; 6(8):1759-67.
  151. Lansang MC, Ma L, Schold JD, Meier-Kriesche HU, Kaplan B. The relationship between diabetes and infectious hospitalizations in renal transplant recipients. Diabetes Care. 2006 Jul; 29(7):1659-60.
  152. Kaplan B, Kirk A. Tacrolimus and sirolimus: when bad things happen to good drugs. Am j Transplant. 2006 Jul; 6(7):1501-2.
  153. Howard DH, Kaplan B. Do report cards influence hospital choice? The case of kidney transplantation Inquiry. 2006 Summer; 43(2):150-9.
  154. Rodrigue JR, Cross NJ, Newman RC, Widows MR, Guenther RT, Kaplan B, Morgan MA, Howard RJ. Patient-reported outcomes for open versus laparoscopic living donor nephrectomy. Prog Transplant. 2006 Jun; 16(2):162-9.
  155. Rodrigue JR, Widows MR, Guenther R, Newman RC, Kaplan B, Howard RJ. The expectancies of living kidney donors: do they differ as a function of relational status and gender? Nephrol Dial Transplant. 2006 Jun; 21(6):1682-8.
  156. Halloran P, Reeve J, Kaplan B. Lies, damn lies, and statistics: the perils of the P value. Am J Transplant. 2006 Jun; 6(1):10-11.
  157. Mehra M, Uber P, Kaplan B. Immunosuppression in cardiac transplantation: science, common sense and the heart of the matter Am J Transplant. 2006 Jun; 6(6):1243-5.
  158. van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006 Apr; 28(2):145-54.
  159. Kaplan B. Overcoming barriers to long-term graft survival. Am J Kidney Dis. 2006 Apr; 47(4 Suppl 2):S52-64.
  160. Srinivas TR, Schold JD, Womer KL, Kaplan B, Howard RJ, Bucci CM, Meier-Kriesche HU. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol. 2006 Mar; 1(2):323-6.
  161. Ehlers SL, Rodrigue JR, Patton PR, Lloyd-Turner J, Kaplan B, Howard RJ. Treating tobacco use and dependence in kidney transplant recipients: development and implementation of a program. Prog Transplant. 2006 Mar; 16 (1):33-7
    View PubMed
  162. Womer KL, Meier-Kriesche HU, Patton PR, Dibadj K, Bucci CM, Fujita S, Croker BP, Howard RJ, Srinivas TR, Kaplan B. Preemptive retransplantation for BK virus nephropathy: successful outcome despite active viremia. Am J Transplant. 2006 Jan; 6(1):209-13.
  163. Schaefer HM, Kaplan B, Helderman JH. Mortality after kidney transplantation: what lessons can we learn from regional and country variation?. Am J Tranplant. 2006 Jan; 6(1):3-4.
  164. Kaplan B. Enteric-coated mycophenolate sodium (myfortic®) - An overview of current and future use in transplantation. Drugs. 2006; 66(Supp 2):1-8.
  165. Srinivas TR, Kaplan B, Schold JD, Meier-Kriesche HU. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation. 2005 Oct 15; 80(2 Suppl):S211-20.
  166. Womer KL, Peng R, Patton PR, Murawski MR, Bucci M, Kaleem A, Schold J, Efron PA, Hemming AW, Srinivas TR, Meier-Kriesche HU, Kaplan B, Clare-Salzler MJ. The effects of renal transplantation on peripheral blood dendritic cells. Clin Transplant. 2005 Oct; 19(5):659-67.
  167. Schold JD, Kaplan B, Chumbler NR, Howard RJ, Srinivas TR, Ma L, Meier-Kriesche HU. Access to quality: evaluation of the allocation of deceased donor kidneys for transplantation. J Am Soc Nephrol. 2005 Oct; 16(10):3121-7.
  168. Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant. 2005 Sep; 5(9):2273-80.
  169. Kaplan B, Meier-Kriesche HU, Minnick P, Bastien MC, Sechaud R, Yeh CM, Balez S, Picard F, Schmouder R. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant. 2005 Aug; 19(4):551-8.
  170. Meier-Kriesche HU, Schold JD, Gaston RS, Wadstrom J, Kaplan B. Kidneys from deceased donors: maximizing the value of a scarce resource. Am J Transplant. 2005 Jul; 5(7):1725-30.
  171. Schold JD, Kaplan B, Howard RJ, Reed AI, Foley DP, Meier-Kriesche HU. Are we frozen in time? Analysis of the utilization and efficacy of pulsatile perfusion in renal transplantation Am J Transplant. 2005 Jul; 5(7):1681-8.
  172. Schold JD, Kaplan B, Baliga RS, Meier-Kriesche HU. The broad spectrum of quality in deceased donor kidneys. Am J Transplant. 2005 Apr; 5(4 Pt 1):757-65.
  173. Halloran PF, Kaplan B. Evolving issues in clinical research. Am J Transplant. 2005 Apr; 5(4 Pt 1):637-8.
  174. Meier-Kriesche HU, Schold JD, Kaplan B. Preservation of long-term renal allograft survival: a challenge for years to come. Am J Transplant. 2005 Mar; 5(3):632-3.
  175. Srinivas TR, Meier-Kriesche HU, Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant. 2005 Feb; 5(2):207-17.
  176. Smith WD, Hatton RC, Fann AL, Baz MA, Kaplan B. Evaluation of drug interaction software to identify alerts for transplant medications. Ann Pharmacother. 2005 Jan; 39(1):45-50.
  177. Smith WD, Hatton RC, Fann AL, Baz MA, Kaplan B. Evaluation of drug interaction software to identify alerts for transplant medications. Ann Pharmacother. 2005 Jan; 39 (1):45-50 Epub 2004 Dec 14
    View PubMed
  178. Kaplan B, Meier-Kriesche HU. Renal transplantation: a half century of success and the long road ahead. J Am Soc Nephrol. 2004 Dec; 15(12):3270-1.
  179. Meier-Kriesche HU, Steffen BJ, Chu AH, Loveland JJ, Gordon RD, Morris JA, Kaplan B. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant. 2004 Dec; 4(12):2058-66.
  180. Meier-Kriesche HU, Morris JA, Chu AH, Steffen BJ, Gotz VP, Gordon RD, Kaplan B. Mycophenolate mofetil vs azathioprine in a large population of elderly renal transplant patients. Nephrol Dial Transplant. 2004 Nov; 19(11):2864-9.
  181. Halloran PF, Langone AJ, Helderman JH, Kaplan B. Assessing long-term nephron loss: is it time to kick the CAN grading system? Am J Transplant. 2004 Nov; 4(11):1729-30.
  182. Kaplan B, Schold J, Srinivas T, Womer K, Foley DP, Patton P, Howard R, Meier-Kriesche HU. Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Transplant. 2004 Oct; 4(10):1709-12.
  183. Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant. 2004 Oct; 4(10):1662-8.
  184. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004 Aug; 4(8):1289-95.
  185. Curtis JJ, Kaplan B. Transplant immunosuppressive drug trials on trial. Am J Transplant. 2004 May; 4(5):671-2.
  186. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004 Mar; 4(3):378-83.
  187. Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc. 2004 Mar; 36(2 Suppl):25S-32S.
  188. Womer KL, Meier-Kriesche HU, Kaplan B. Which calcineurin inhibitor . Eur J Hosp Pharm. 2004; 10(5):15-6.
  189. Srinivas TR, Kaplan B, Meier-Kriesche HU. Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother. 2003 Dec; 4(12):2325-45.
  190. Kaplan B, Schold J, Meier-Kriesche HU. Poor predictive value of serum creatinine for renal allograft loss. Am J Transplant. 2003 Dec; 3(12):1560-5.
  191. Kaplan B, Schold JD, Meier-Kriesche HU. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol. 2003 Nov; 14(11):2980-4.
  192. Kaplan B, Schold J, Meier-Kriesche HU. Overview of large database analysis in renal transplantation. Am J Transplant. 2003 Sep; 3(9):1052-6.
  193. Kovarik JM, Kaplan B, Silva HT, Kahan BD, Dantal J, McMahon L, Berthier S, Hsu CH, Rordorf C. Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. Am J Transplant. 2003 May; 3(5):606-13.
  194. Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, Kaplan B. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation. 2003 Apr 27; 75(8):1341-6.
  195. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation. 2003 Apr 27; 75(8):1291-5.
  196. Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, Kaplan B. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant. 2003 Jan; 3(1):68-73.
  197. Cibrik DM, Kaplan B, Campbell DA, Meier-Kriesche HU. Renal allograft survival in transplant recipients with focal segmental glomerulosclerosis. Am J Transplant. 2003 Jan; 3(1):64-7.
  198. Rudich SM, Kaplan B, Magee JC, Arenas JD, Punch JD, Kayler LK, Merion RM, Meier-Kriesche HU. Renal transplantations performed using non-heart-beating organ donors: going back to the future? Transplantation. 2002 Dec 27; 74(12):1715-20.
  199. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation. 2002 Nov 27; 74(10):1377-81.
  200. Kaplan B, Meier-Kriesche HU. Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant. 2002 Nov; 2(10):970-4.
  201. Cibrik DM, Kaplan B, Arndorfer JA, Meier-Kriesche HU. Renal allograft survival in patients with oxalosis. Transplantation. 2002 Sep 15; 74(5):707-10.
  202. Srinivas TR, Meier-Kriesche HU, Kaplan B, Bennett WM. Response to "Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared with lisinopril". Transplantation. 2002 Jul 15; 74(1):139.
  203. Kovarik JM, Kaplan B, Tedesco Silva H, Kahan BD, Dantal J, Vitko S, Boger R, Rordorf C. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation. 2002 Mar 27; 73(6):920-5.
  204. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol. 2002 Mar; 13(3):769-72.
  205. Kaplan B, Srinivas TR, Meier-Kriesche HU. Factors associated with long-term renal allograft survival. Ther Drug Monit. 2002 Feb; 24(1):36-9.
  206. Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002 Jan 15; 73(1):70-4.
  207. Kaplan B, Meier-Kriesche HU. Mortality risk assessment after renal transplantation. Clin Transpl. 2002:131-6.
  208. Meier-Kriesche HU, Kaplan B. Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. Am J Transplant. 2002 Jan; 2(1):100-4.
  209. Meier-Kriesche HU, Cibrik DM, Ojo AO, Hanson JA, Magee JC, Rudich SM, Leichtman AB, Kaplan B. Interaction between donor and recipient age in determining the risk of chronic renal allograft failure. J Am Geriatr Soc. 2002 Jan; 50(1):14-7.
  210. Kaplan B. Steroid-sparing immunosuppression: Historical view of steroid withdrawal . Transplantation. 2002.
  211. Meier-Kriesche HU, Kaplan B. Death after graft loss: a novel endpoint for renal transplantation. Transplant Proc. 2001 Nov-Dec; 33(7-8):3405-6.
  212. Meier-Kriesche HU, Kaplan B. Cyclosporine microemulsion and associated with decreased chronic allograft failure and improved long-term graft survival as compared to sandimmune. Tranplant Proc. 2001 Nov-Dec; 33(7-8):3422-3.
  213. Neier-Kriesche HU, Srinivas TR, Kaplan B. Interaction between acute rejection and recipient age on long-term renal allograft survival. Transplant Proc. 2001 Nov; 33(7-8):3425-6.
  214. Yamani A, Myers-Powell B, Witcup SM, Cohen SB, Kanter ED, Kaplan B, Zarbin MA. Visual loss after renal transplantation. Retina. 2001 Oct; 21(5):553-9.
  215. Matalon A, Markowitz GS, Joseph RE, Cohen DJ, Saal SD, Kaplan B, D'Agati VD, Appel GB. Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients. Clin Nephrol. 2001 Oct; 56(4):271-8.
  216. Friedman GS, Meier-Kriesche HU, Kaplan B, Mathis AS, Bonomini L, Shah N, DeFranco P, Jacobs M, Mulgaonkar S, Geffner S, Lyman N, Paraan C, Walsh C, Belizaire W, Tshibaka M. Hypercoagulable states in renal transplant candidate: impact of anticoagulation upon incidence of renal allograft thrombosis. Transplantation. 2001 Sep 27; 72(6):1073-8.
  217. Meier-Kriesche HU, Ojo A, Hanson J, Kaplan B. Hepatitis C and outcomes in renal transplantation. Transplantation. 2001 Jul 27; 72(2):241-4.
  218. Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation. 2001 Jul 27; 62(2):241-4.
  219. Meier-Kriesche HU, Ojo A, Port F, Arndorfer J, Cibrik D, Kaplan B. Survival improvement among patients with end-stage renal disease: trends over time for transplant patients and wait-listed patients. J Am Soc Nephrol. 2001 jun; 6(1293-6). Epub 0
  220. Kahan BD, Kaplan B, Lorber MI, Winkler M, Cambon N, Boger RS. RAD in de-novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation. 2001 May 27; 71(10):1400-6.
  221. Polsky D, Weinfurt K, Kaplan B, Kim J, Fasteneau J, Schulman K. An economic assessment of simulect vs antithymocyte globulin immunoprophylaxis . Nephrol Dial Transplant. 2001 May; 16(5):1028-33.
  222. Mathis AS, DiRenzo T, Friedman G, Kaplan B, Adamson R. Sex and ethnicity may chiefly influence the interaction of fluconazole with calcineurin inhibitors. Transplantation. 2001 Apr 27; 61(8):1069-75.
  223. Meier-Kriesche HU, Ojo A, Hanson J, Kaplan B. Exponentially increased risk of infectious death in older renal transplant recipients: a comparison of transplanted and wait-listed end stage renal disease patients. Kidney Int. 2001 Apr; 59(4):1539-43.
  224. Kovarik JM, Prescovitz MD, Sollinger HW, Kaplan B, Legendre C, Salmela K, Book BK, Gerbeau C, Girault D, Somberg K. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. Clin Transplant. 2001 Apr; 15(2):123-30.
  225. Ojo AO, Hanson JA, Meier-Kriesche H, Okechukwu CN, Wolfe RA, Leichtman AB, Agodoa LY, Kaplan B, Port FK. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidate. J Am Soc Nephrol. 2001 Mar; 12(3):589-97.
  226. Meier-Kriesche HU, Ojo AO, Leichtman AB, Magee JC, Rudich SM, Hanson JA, Cibrik DM, Kaplan B. Interaction of mycophenolate mofetil and HLA matching on renal allograft survival. Transplantation. 2001 Feb 15; 71(3):398-401.
  227. Meier-Kriesche HU, Ojo AO, Leavey SF, Hanson JA, Leichtman AB, Magee JC, Cibrik DM, Kaplan B. Gender differences in the risk for chronic allograft failure. Transplantation. 2001 Feb 15; 71(3):429-32.
  228. Ojo AO, Meier-Kriesche HU, Arndorfer JA, LeichtmanAB, Magee JC, Cibrik DM, Wolfe RA, Port FK, Agodoa L, Kaufman DB, Kaplan B. Long-term benefit of kidney-pancreas transplants in type 1 diabetics . Transplant Proc. 2001 Feb-Mar; 33(1-2):1670-2.
  229. Meier-Kriesche HU, Ojo AO, Port FK, Magee JC, Leichtman AB, Punch JD, Kaplan B. Recipient age as independent risk factor for chronic renal allograft failure . Transplant Proc. 2001 Feb-Mar; 33(1-2):1113-4.
  230. Meier-Kriesche HU, Ojo AO, Hanson JA, Leichtman AB, Lake K, Cibrik DM, Punch JD, Kaplan B. Need for individualized immunosuppression in elderly renal transplant recipients. Transplant Proce. 2001 Feb-Mar; 33(1-2):1190-1.
  231. Meier-Kriesche H, Ojo AO, Arndorder JA, Magee JC, Cibrik DM, Leichtman AB, Campbell DA, Kaplan B. Mycophenolate mofetil decreases the risk for chronic renal allograft failure. Transplant Proc. 2001 Feb-Mar; 33(1-2):1005-6.
  232. Meier-Kriesche HU, Port FK, Ojo AO, Leichtman AB, Rudich SM, Arndorfer JA, Punch JD, Kaplan B. Deleterious effect of waiting time on renal transplant outcome. Transplant Proc. 2001 Feb-Mar; 33(1-2):1188-9.
  233. Arndorfer JA, Meier-Kriesche HU, Ojo AO, Gruber SA, Cibrik Dm, Lake KD, Kaplan B, Leichtman AB. Time to first graft loss as a risk factor for second renal allograft loss. Transplant Proc. 2001 Feb-Mar; 33(1-2):1188-9.
  234. Meier-Kriesche HU, Ojo AO, Leavey S, Cibrik D, Arndorfer JA, Leichtman AB, Punch J, Armstrong D, Kaplan B. Differences in etiology of graft loss in female renal transplant recipients. Transplant Proce. 2001 Feb-Mar; 33(1-2):1288-90.
  235. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman A, Magee JC, Cibrik D, Wolfe RA, Port FK, Agodoa L, Kaufman DB, Kaplan B. The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation. 2001 Jan 15; 71(1):82-90.
  236. Ojo, AO, Meier-Kriesche HU, Hanson JA, Leichtman A, Magee JC, Cibrik D, Wolfe RA, Port FJ, Agodoa L, Kaufman DB, Kaplan B. Type of transplant and outcome in patients with diabetes mellitus and end stage renal disease. Transplantation. 2001 Jan 15; 71(1):82-90.
  237. Okechukwu N, Meier-Kriesche HU, Armstrong D, Campbell D, Gerbeau C, Kaplan B. Removal of Basliiximab by Plasmapheresis . Am J Kidney Dis. 2001 Jan; 37(1):E11.
  238. Kovarik J, Kahan B, Kaplan B, Lober M, Winkler M, Roouily M, Gerbeau C, Cambon N, Boger B, Rordorf C, Everolimus Phase Study Group. Longitudinal pharmacokinetics of everolimus and its influence on cyclosporine in de novo renal transplant recipients. Clin Pharmacol Ther. 2001 Jan; 69(1):48-56.
  239. Meier-Kriesche HU, Kaplan B. Immunosuppression in elderly renal transplant recipients: are current regimens too aggressive?. Drugs Aging. 2001; 18(10):751-9.
  240. Cibrik DM, Kaplan B, Meier-Kriesche HU. Role of anti-interleukin-2 receptor antibodies in kidney transplantation. BioDrugs. 2001; 15(10):655-66.
  241. Meier-Kriesche HU, Punch JD, Leichtman AB, Cibrik D, Ojo A, Hanson J, Kaplan B. Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. J Am Soc Neph. 2000 Dec; 11(12):2366-70.
  242. Meier-Kriesche HU, Ojo A, Hanson J, Cibrik D, Punch J, Leichtman A, Kaplan B. Increase impact of acute rejection on chronic allograft failure in recent era. Transplatnation. 2000 Oct 15; 70(7):1098-1100.
  243. Meier-Kriesche HU, Kaza H, Palekar S, Friedman G, Mulgaonkar S, Ojo A, Kaplan B. The effect of Daclizumab in a high-risk renal transplant population. Clin Transplant. 2000 Oct; 14(5):509-13.
  244. Meier-Kriesche HU, Port FK, Ojo AO, Rudich SM, Hanson JA, Cibrik DM, Leichtman AB, Kaplan B. Effect of waiting time on renal transplant outcome. Kidney Int. 2000 Sep; 58(3):1311-7.
  245. Meier-Kriesche HU, Ojo AO, Cibrik DM, Hanson JA, Leichtman JC, Magee JC, Port FK, Kaplan B. Relationship of recipient age and development of chronic allograft failure. Transplantation. 2000 Jul 27; 70(2):306-10.
  246. Gruber SA, Katz S, Kaplan B, Clark J, Chen P, El-Sabrout R, Kerman R. Initial results of solitary pancreas transplants performed without regard to donor/recipient HLA mismatching. Transplantation. 2000 Jul 27; 70(2):388-91.
  247. Meier-Kriesche HU, Ojo A, Hanson J, Cibrik D, Magee J, Leichtman A, Kaplan B. African-American renal transplant recipients experience decreased risk of death due to infection: possible implications for immunosuppressive strategies. Transplantation. 2000 Jul 26; 70(2):375-9.
  248. Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman AB, Kaplan B. Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation. 2000 Jun 15; 69(11):2337-9.
  249. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation. 2000 Jun 15; 69(11):306-10.
  250. Friedman GS, Wik D, Silva L, Abdou JC, Meier-Kriesche HU, Kaplan B, Bonomini L, DeFranco P, Lyman N, Mulgaonkar S, Jacobs M. Allograft loss in renal transplant patients with Fabry's disease and activated protein C resistance. Transplantation. 2000 May 27; 69(10):2099-2102.
  251. Kaplan B, Meier-Kriesche HU, Vaghela M, Friedman G, Mulgaonkar S, Jacobs M. Withdrawal of mycophenolate mofetil in stable renal transplant recipients. Transplantation. 2000 Apr 27; 69(8):1726-8.
  252. Kaplan B, Cheema A, Friedman G, Shah N, Bonomini L, Mulgaonkar S, Nambi S, DeFranco P. Unmasking of primary hyperaldosteronism by renal transplantation. Transplantation. 2000 Apr 15; 55(6):949.
  253. Whang M, Katz L, Ongcapin E, Geffner S, Friedman GS, Mulgaonkar SP, Kaplan B. Nephrogenic adenomas occurring in a patient with simultaneous kidney-pancreas transplant. Urology. 2000 Apr 15; 1503-5.
  254. Meier-Kriesche HU, Ojo A, Hanson J, Cibrik D, Lake K, Agodoa LY, Leichtman A, Kaplan B. Increased immunosuppressive vulnerability in elderly renal transplant recipients. Transplantation. 2000 Mar 15; 69(5):885-9.
  255. Meier-Kriesche HU, Shaw LM, Korecka M, Kaplan B. Pharmacokinetics of mycophenolate acid in renal insufficiency . Ther Drug Monit. 2000 Feb; 22(1):27-30.
  256. Shaw L, Kaplan B, Koreca M, Denofrio D, Brayman K. Pharmacokinetics and concentration control studies with mycophenolate mofetil in adults after transplantation. Ther Drug Monit. 2000 Feb; 22(1):14-9.
  257. Meier-Kriesche HU, Palenkar SS, Friedman GS, Mulgaonkar SP, Goldblat MV, Kaplan B. Efficacy of Daclizumab in African-American and Hispanic renal transplant population. Transpl Int. 2000; 13(2):142-5.
  258. Meier-Kriesche HU, Kaplan B. Toxicity and efficacy of Sirolimus: relationship to whole blood concentrations. Clin Ther. 2000; 22(Suppl B):B93-100.
  259. Shaw LM, Kaplan B, Brayman KL. Advances in therapeutic drug monitoring for immunosuppressants: a review of sirolimus. Introduction and overview. Clin Ther. 2000; 22(B1-B13).
  260. Meier-Kriesche HU, Friedman G, Mulgaonkar S, Jacobs M, Kaplan B. Infectious complications in geriatric renal transplant patients: comparison of two immunosuppressive protocols. Transplantation. 1999 Nov 27; 78(10):1496-1502.
  261. Meier-Kriesche HU, Vaghela M, Thambuganipalle R, Friedman G, Jacobs M, Kaplan B. Effect of body mass index on long-term renal allograft survival. Transplantation. 1999 Nov 15; 78(9):1294-7.
  262. Kaplan B, Meier-Kriesche HU, Friedman G, Mulgaonkar S, Gruber S, Korecka M, Shaw L. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol. 1999 Jul; 39(7):715-20.
  263. Kaplan B, Meier-Kriesche HU, Jacobs MG, Friedman G, Bonomini L, DeFranco P, Gelfand E, Mulgaonkar S. Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain. Am J Kidney Dis. 1999 Jul; 34(1):65-8.
  264. Kaplan B, Meier-Kriesche HU, Napoli K, Kahan BD. Correlation between pretansplantation test dose cyclosporine pharmacokinetic profiles and post-transplantation sirolimus blood levels in renal transplant recipients . Ther Drug Monit. 1999 Feb; 21(1):44-9.
  265. Meier-Kriesche HU, Alloway R, Gaber AO, Canafax D, Kaplan B. A limited sampling strategy for the estimation of 12-hour SangCya and neural AUCs in renal transplant recipients. J Clin Pharmacol. 1999 Feb; 39(2):166-71.
  266. Kaplan B, Lown K, Craig R, Abecassis M, Kaufman D, Leventhal J, Stuart F, Meir-Kriesche HU, Fryer J. Low bio-availability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal p-glycoprotein activity. Transplantation. 1999 Jan 27; 67(2):333-5.
  267. Kaplan B, Wang T, Henthorn T, Mujais S. Evaluations of urea kinetics using a stable isotope methodology and pharmacokinetic modeling. Artif Organs. 1999 Jan; 23(1):44-50.
  268. Kaplan B. Pharmacokinetics and pharmacodynamics of immunosuppressive agents. Graft. 1999:2.
  269. Meier-Kriesche HU, Kaplan B, Brannan P, Kahan BD Poertman RJ. A limited sampling for the estimation of eight-hour neural areas under the curve in renal transplantation. Ther Drug Monit. 1998 Aug; 20(4):401-7.
  270. Kaplan B, Friedman G, Jacobs M, Viscuso R, Lyman N, DeFranco P, Bonomini B, Mulgaonkar SP. Potential interaction of troglitazone and cyclosporine. Transplantation. 1998 May 27; 65(10):1399-1400.
  271. Kaplan B, Gruber SA, Nallamathou R, Katz SM, Shaw LM. Decreased protein binding of mycophenolic acid associated with leukopenia in pancreas transplant recipient with renal failure . Transplantation. 1998 Apr 27; 65(8):1127-9.
  272. Shaw L, Kaplan B, Brayman KL. Prospective investigations of concentration - clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring . Clin Chem. 1998 Feb; 44(2):381-7.
  273. Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formation coadministration on the pharmacokinetics of each agent. Clin Pharmaco Ther. 1998 Jan; 63(1):48-53.
  274. Adachi J, Grimm E, Johnson P, Uthman M, Kaplan B, Rakita R. Human granulocytic ehrlichiosis in a renal transplant patient: case report and review of the literature. Tranplantation. 1997 Oct 27; 64(8):1139-42.
  275. Kaplan B, Meier-Kriesche HU, Napoli K, Kahan BD. A limited sampling strategy for estimating Sirolimus area-under-the concentration curve. Clin Chem. 1997 Mar; 53(3):539-40.
  276. Fryer JP, Blondin B, Stadler C, Ivancic D, Ratmer U, Kaplan B. Inhibition of human serum mediated lysis of porcine endothelial cells using a novel peptide which blocks C1Q binding to xenoantibody. Transplant Proc. 1997 Feb-Mar; 29(1-2):883.
  277. Abecassis MM, Koffron AJ, Kaplan B, Buckingham M, Muldoon JP, Cribbins AJ, Kaufman DB, Fryer JP, Stuart J, Stuart FP. The role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy? . Transplantation. 1997 Jan 27; 63(2):275-9.
  278. Abecassis MM, Koffron AJ, Kaplan B, Buckingham M, Muldoon JP, Cribbins AJ, Kaufman DB, Freyer JP, Stuart J, Stuart FP. Role of PCR in the diagnosis and management of CMV in Solid organ recipients; what is the predicitive value for the development of disease and should PCR be used to guide antiviral therap? . Transplant Proc. 1996 Dec; 28(6 Supp 2):2-4.
  279. Kaplan B, Wang Z, Abecassis MM, Fryer JP, Stuart FA, Kaufman DB. Frequency of hyperkalemia in recipients of simultaneous pancreas/kidney transplant with bladder drainage. Transplantation. 1996 Oct 27; 62(8):1174-5.
  280. Kaplan B, Wang Z, Abecassis M, Stuart FB, Kaufman DB. Cyclosporine pharmacokinetics and risk of recurrent rejection in recipients of simultaneous pancreas/kidney transplants. Ther Drug Moit. 1996 Oct; 18(5):556-61.
  281. Shaw L, Kaplan B, Kaufman DB. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin Chem. 1996 Aug; 42(8 Pt 2):1316-21.
  282. Yedidag EN, Koffron AJ, Mueller KH, Kaplan B, Kaufman DB, Fryer JP, Stuart FP, Abecassis M. Acyclovir triphosphate inhibits the diagnostic polymerase chain reaction for cytomegalovirus. Transplantation. 1996 Jul 27; 62(2):238-42.
  283. Shaw LM, Annesley TM, Kaplan B, Brayman KL. Analytic requirements for immunosuppressive drugs in clinical trials. Ther Drug Monit. 1995 Dec; 17(6):577-83.
  284. Kaplan B, Cooper J, Lager D, Abecassis M. Hepatic infarction in a hemodialysis patient with systemic lupus erythematosus. Am J Kidney Dis. 1995 Nov; 26(5):785-7.
    View PubMed
  285. Kaplan B, Wang Z, Keilani T, Kaufman DB. The specificity of monoclonal fluorescence polarization immunoassay for cyclosporine in recipients of simultaneous pancreas-kidney transplants . Ther Drug Monit. 1995 Oct; 17(5):499-503.
  286. Kaufman DB, Kaplan B, Kanwar YS, Abecassis M, Stuart FP. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. Transplantation. 1995 Jun; 59(12):1736-9.
  287. Schlueter W, Keilani T, Hizon M, Kaplan B, Batlle DC. On the mechanism of impaired distal acidification in hyperkalemic renal tubular acidosis: evaluation with amiloride and bumetanide. J Am Soc Nephrol. 1992 Oct; 3(4):954-64.
  288. Kaplan B, Want T, Rammohan M, del Greco F, Molteni A, Atkinson AJ Jr. Response to head-up tilt in cramping and noncramping hemodialysis patients. Int J Clin Pharmacol Ther Toxicol. 1992 May; 30(5):173-80.
  289. Kaplan B, Drumlovsky FA. Phenytoin in end-stage renal disease. Int J Artif Organs. 1992 Feb; 15(2):69-70.
  290. Sollinger H, Kaplan B, Prescovitz M, Philosophe B, Roza A, Brayman K, Somberg K. Basiliximab versus antithymocyte globlin for prevention of acute renal allograft rejection. Transplantation. 20001 Dec 27; 72(12):1915-9.